1. Home
  2. NUW vs LUNG Comparison

NUW vs LUNG Comparison

Compare NUW & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen AMT-Free Municipal Value Fund

NUW

Nuveen AMT-Free Municipal Value Fund

HOLD

Current Price

$13.87

Market Cap

251.7M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.29

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUW
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.7M
57.9M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
NUW
LUNG
Price
$13.87
$1.29
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
51.1K
538.0K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$13.42
$1.13
52 Week High
$14.70
$3.88

Technical Indicators

Market Signals
Indicator
NUW
LUNG
Relative Strength Index (RSI) 34.68 45.70
Support Level $13.83 $1.19
Resistance Level $13.94 $1.45
Average True Range (ATR) 0.11 0.09
MACD -0.01 0.01
Stochastic Oscillator 7.60 37.04

Price Performance

Historical Comparison
NUW
LUNG

About NUW Nuveen AMT-Free Municipal Value Fund

Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: